Every 8-K that Biohaven Ltd. (BHVN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BHVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHVN filings page.
Biohaven Ltd. (BHVN) reports that the U.S. FDA issued a partial clinical hold on the BHV-7000 epilepsy program on September 4, 2026, pausing new patient enrollment while additional nonclinical studies further characterize a specific rodent metabolite.
Dosing continues for more than 600 already randomized patients across the BHV-7000 program, including BHV7000-303, which is fully enrolled, with topline data still expected in the second half of 2026. Over 1,200 participants have received BHV-7000 to date, and the safety profile has generally been described as safe and well-tolerated. BHV7000-302 and the open-label extension study will keep dosing but will not enroll new patients until the additional nonclinical data are available.
Separately, on August 26, 2026, Biohaven’s subsidiary Biohaven Bioscience Ireland Limited entered into a License Agreement under which SK Biopharmaceuticals will receive an exclusive, royalty-bearing, worldwide license to Biohaven’s Kv7 ion channel platform, including BHV-7000, subject to closing conditions including Hart-Scott-Rodino review. All clinical and nonclinical data, including metabolite characterization, were disclosed to SK Biopharmaceuticals before signing.
Biohaven Ltd. (BHVN) announced a strategic global license and collaboration under which its wholly owned subsidiary Biohaven Bioscience Ireland Limited will grant SK Biopharmaceuticals an exclusive, royalty-bearing worldwide license to Biohaven’s Kv7 ion channel platform, led by opakalim (BHV-7000), for epilepsy and other indications, effective upon closing.
SK Biopharmaceuticals will pay Biohaven $400 million in near-term cash (including $350 million at closing and $50 million one year later) and up to $150 million in development and regulatory milestones, plus tiered royalties on global net sales of opakalim and other licensed products. SK Biopharmaceuticals will also reimburse certain pre-closing costs and fund agreed development activities while Biohaven completes ongoing Phase 2/3 RISE 2 and RISE 3 trials and prepares an NDA for opakalim.
In a related agreement, SK Biopharmaceuticals will assume up to $245 million in contingent milestone obligations and a mid‑single‑digit worldwide royalty owed under a prior acquisition agreement for the Kv7 platform. Closing is subject to antitrust review, including under the Hart‑Scott‑Rodino Act, and other customary conditions.
Biohaven Ltd. reported second quarter 2026 results alongside extensive R&D updates across immunology, epilepsy, obesity, neuroscience and oncology. The company highlighted its extracellular protein degrader platforms (MoDE and TRAP), including BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy, both showing deep, rapid reductions in disease-driving antibodies with favorable safety profiles and progressing toward or into pivotal trials in 2026.
Opakalim (BHV-7000) demonstrated durable seizure control across multiple epilepsy types with a differentiated tolerability profile, with topline Phase 2/3 focal epilepsy data expected in the second half of 2026. Oncology programs BHV-1530 and BHV-1510 continue under collaborations with Regeneron, while additional pipeline assets taldefgrobep alfa, BHV-8100 and BHV-8000 advance in obesity, neuroimmunology and Parkinson’s disease.
Financially, cash, cash equivalents, marketable securities and restricted cash totaled approximately $270.5 million as of June 30, 2026. Second quarter R&D expenses decreased to $100.8 million from $184.4 million a year earlier, and net loss narrowed to $137.3 million, or $0.91 per share, with non-GAAP adjusted net loss of $118.1 million, or $0.78 per share.
Biohaven Ltd. appointed John Yetimoglu to its Board of Directors, effective August 6, 2026. He will serve in the director class whose term expires at the 2027 Annual Meeting of Shareholders and has been named to the Board’s Nominating and Governance Committee. The company states there is no arrangement or understanding with any other person regarding his selection, no family relationships with other directors or executive officers, and no related-party transactions involving him that require disclosure under Item 404(a) of Regulation S‑K.
Under Biohaven’s compensation policy for non‑employee directors, Mr. Yetimoglu is entitled to options to purchase common shares with an aggregate grant date fair value of $713,875, vesting 25% on grant and 25% on each of the following three anniversaries of grant, subject to his continuous service. He will also receive a $57,000 annual retainer for his service as a director and committee member.
Biohaven Ltd. announced several scientific leadership changes. Effective July 13, 2026, Bruce Car, Ph.D., will retire as Chief Scientific Officer and move to a part-time role as Chief Innovation Officer, focusing on scientific initiatives and external collaborations, including multiple assets in the collaboration with Bexorg, Inc. He will continue as an executive officer and his salary will be reduced by fifty percent to reflect his schedule.
At the same time, David Pirman, Ph.D., is promoted to Executive Vice President and Head of Discovery, leading Biohaven’s internal drug-discovery organization and research programs. The company also designated Warren Volles, General Counsel and Chief Legal Officer, as an executive officer, formalizing his role in guiding Biohaven’s legal function.
Biohaven Ltd. provided extensive research and development updates, highlighting new clinical data across epilepsy, autoimmune and neuroscience programs. Its Kv7.2/7.3 activator opakalim in idiopathic generalized epilepsy tripled median time to a second generalized tonic-clonic seizure to 141 days versus 47 days on placebo in a small randomized trial and showed no somnolence, dizziness or fatigue. In focal epilepsy, an open-label extension analysis found 54% of six‑month completers on opakalim 75 mg once daily achieved at least a 50% seizure reduction, with low central nervous system adverse event rates compared with other antiseizure medicines. Biohaven also reported Phase 1b data for its extracellular degraders: BHV‑1300 reduced Graves’ disease TSHR‑IgG1 autoantibodies by over 80% with associated normalization of thyroid hormones, while BHV‑1400 lowered pathogenic Gd‑IgA1 by more than 60% within 48 hours and 70% within one month in IgA nephropathy, alongside early improvements in kidney function markers. Early safety across these programs was described as favorable, and Biohaven plans pivotal Phase 3 trials in Graves’ disease and IgA nephropathy by mid‑2026 while advancing additional CNS candidates such as PKM2 activator BHV‑8100 and tinnitus spray BHV‑1955.
Biohaven Ltd. entered into Amendment No. 2 to its Equity Distribution Agreement with J.P. Morgan Securities LLC, establishing an “at-the-market” equity offering program. From May 4, 2026, the company may sell up to an aggregate offering price of $350.0 million in common shares through J.P. Morgan as manager.
Shares may be sold on the New York Stock Exchange or via other negotiated transactions at prevailing market prices, with actual sales determined over time by the company’s capital needs and market conditions. The program is issued under an effective shelf registration statement and related base prospectus and prospectus supplement filed on May 4, 2026.
Biohaven Ltd. reported first quarter 2026 results showing a smaller loss and stronger balance sheet while advancing multiple late-stage drug programs. Net loss narrowed to $130.5 million, or $0.88 per share, compared with $221.7 million, or $2.17 per share, a year earlier.
R&D expenses fell to $103.8 million from $187.6 million, mainly from program reprioritization and lower preclinical and share-based compensation costs. Cash, cash equivalents, marketable securities and restricted cash totaled $351.8 million as of March 31, 2026, supporting a broad pipeline across epilepsy, obesity, immunology, oncology and Parkinson’s disease.
The company expects pivotal epilepsy data for opakalim and Phase 2 obesity data for taldefgrobep alfa in the second half of 2026, and plans to start pivotal trials for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy by mid-2026. Non-GAAP adjusted net loss improved to $102.2 million, or $0.69 per share, as Biohaven continues disciplined cost management while progressing its clinical programs.
Biohaven Ltd. reported the results of its 2026 annual meeting of shareholders. Shareholders elected Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin as directors for terms expiring at the 2029 annual meeting, each receiving over 76 million votes in favor and more than 14 million votes against, with additional abstentions and 32,137,064 broker non-votes.
Shareholders also approved the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, with 123,723,636 votes for, 214,123 against, and 1,410,634 abstentions. In addition, they approved the non-binding advisory vote on compensation for the company’s named executive officers, with 87,521,620 votes for, 4,202,883 against, 1,486,826 abstentions, and 32,137,064 broker non-votes.
Biohaven Ltd. reported another year of heavy investment in its pipeline, posting a 2025 net loss of $738.8M, or $6.86 per share, compared with a $846.4M loss in 2024. Research and development expenses were $635.1M, down from $795.9M, reflecting prior one-time costs and a shift toward three late-stage programs in immunology, epilepsy and obesity.
Cash, cash equivalents, marketable securities and restricted cash totaled about $322.0M as of December 31, 2025. After year-end, Biohaven raised net proceeds of $178.9M by issuing 17.2 million common shares and had previously completed a roughly $200M 2025 equity offering and an Oberland Capital financing of up to $600M.
The company highlighted strong early clinical signals from its MoDE™ and TRAP™ degrader platform (BHV‑1300 for Graves’ disease and BHV‑1400 for IgA nephropathy), its Kv7 ion channel activator opakalim for focal epilepsy, and myostatin‑activin inhibitor taldefgrobep for obesity, with multiple pivotal and Phase 2/3 readouts expected in the second half of 2026.
Biohaven Ltd. disclosed that it will be making an investor presentation on January 12, 2026. The company has prepared an investor slide deck, described as an Investor Presentation dated January 2026, and made it available as an exhibit to this report so that the broader market has access to the same information shared with investors.
The presentation materials are furnished for informational purposes only under Regulation FD, meaning they are not treated as formally filed financial statements or incorporated into other securities law documents unless specifically referenced in the future.
Biohaven Ltd. agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at a purchase price of $10.00 per share. The company expects to receive approximately $125 million in gross proceeds upon settlement, before fees and other expenses. These new shares are being issued as a block transaction under Biohaven’s existing “at-the-market” offering program, which is registered on Form S-3 and described in a prospectus dated October 2, 2023 and a prospectus supplement dated August 16, 2024.
Biohaven Ltd. (BHVN) completed a registered public offering of 26,833,334 common shares at $7.50 per share, including the full exercise of the underwriters’ option to purchase 3,500,000 additional shares. Gross proceeds to the company were approximately $200 million before underwriting discounts, commissions, and expenses.
The offering was underwritten by J.P. Morgan and Goldman Sachs and conducted under an effective shelf registration, using a base prospectus dated October 2, 2023 and a prospectus supplement dated November 12, 2025. The underwriting agreement includes customary representations, conditions, indemnification, and termination provisions.
Biohaven Ltd. (BHVN) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The company reported this event on November 10, 2025.
The information was provided under Item 2.02 and includes Exhibit 99.1 titled “Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments.” As noted under General Instruction B.2., the Item 2.02 information and Exhibit 99.1 are furnished, not filed.
Biohaven Ltd. (BHVN) reported that the FDA's Division of Neurology 1 extended the PDUFA review for the troriluzole NDA by three months in May 2025 to allow a full review of recent submissions. At that time the Division had planned an advisory committee meeting to discuss the application.
On August 21, 2025 the Division informed the company that an advisory committee meeting is no longer needed for regulatory decision making. The FDA's decision on the NDA is expected during the fourth quarter of 2025. The report and Exhibit 99.1 are being furnished and are not "filed" for Section 18 purposes.
Biohaven Ltd. filed a prospectus supplement covering the resale by a selling shareholder of 3,588,688 common shares that were issued as share consideration under an amended acquisition agreement.
The amendment to the Knopp Biosciences purchase arrangement replaces a scaled high single digit to low teens royalty with a flat mid-single digit royalty on BHV-7000 and related pipeline programs. It also removes up to $562.5 million in commercial sales-based milestones and reduces developmental and regulatory milestones from up to $575 million to up to $210 million tied to BHV-7000 approvals across multiple regions, plus up to $60 million tied to U.S. approval of other Kv7 programs. Biohaven can choose to pay these contingent milestones in cash or in its common shares.
Biohaven Ltd. furnished a Current Report on Form 8-K to announce a press release reporting its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the cover page of the report is provided in Inline XBRL as Exhibit 104.
The filing states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference in other filings except by specific reference. The registrant is organized in the British Virgin Islands, its common shares trade under BHVN on the New York Stock Exchange, and the report is signed by Chief Financial Officer Matthew Buten.